Vita Life Sciences Limited (ASX:VLS) Insider Purchases A$19,185.70 in Stock

Vita Life Sciences Limited (ASX:VLS) insider Peter Osborne acquired 11,090 shares of the business’s stock in a transaction dated Tuesday, May 6th. The stock was acquired at an average price of A$1.73 ($1.11) per share, with a total value of A$19,185.70 ($12,298.53).

Peter Osborne also recently made the following trade(s):

• On Monday, February 24th, Peter Osborne bought 4,820 shares of Vita Life Sciences stock. The shares were acquired at an average cost of A$1.92 ($1.23) per share, for a total transaction of A$9,254.40 ($5,932.31).

Vita Life Sciences Stock Performance

The stock has a market capitalization of $107.10 million, a P/E ratio of 11.27 and a beta of 0.46. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.96 and a quick ratio of 1.57.

Vita Life Sciences Increases Dividend

The company also recently declared a Final dividend, which was paid on Thursday, April 10th. Stockholders of record on Thursday, April 10th were given a dividend of $0.065 per share. This is a boost from Vita Life Sciences’s previous Final dividend of $0.06. The ex-dividend date of this dividend was Thursday, March 20th. This represents a dividend yield of 3.42%. Vita Life Sciences’s payout ratio is presently 41.18%.

About Vita Life Sciences

Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company also offers various minerals, herbs, and superfoods. In addition, it provides products for therapeutic areas, such as nervous system; nutritionals; urinary health; weight management; immunity; skin, hair, and nails; liver and digestion; fertility, pregnancy, and postpartum; blood sugar management; cardiovascular health; pain and inflammation; men, women, and children's health; antioxidants; bones, joints, and muscles; and eye health.